Liyang Chip Ends Its Planned 100% Guoxin Micro Acquisition After 20 Months

Liyang Chip has terminated its planned acquisition of 100% of Guoxin Micro after roughly 20 months of due diligence and internal review. The decision closes a proposed deal that was meant to add specialized chip verification capabilities to Liyang Chip’s existing testing business.

The companies signed a termination agreement on September 4, 2026. According to the disclosure, no formal equity-transfer agreement was completed, Liyang Chip paid no consideration, and neither side must compensate the other.

That clean exit limits the immediate financial damage. It does not remove the strategic question created by the cancellation. Liyang Chip still lacks the specialty-testing qualifications and laboratory capabilities that made Guoxin Micro attractive in the first place.

The timing sharpens that tension. Liyang Chip returned to profit during the first half of 2026 as demand improved across memory, automotive electronics, industrial control, and edge-intelligence chips. Management must now decide whether organic investment can close its capability gap without distracting from that recovery.

What Exactly Ended in the Liyang Chip Acquisition

The cancellation ends an acquisition proposal, not a completed transaction or an operational integration.

Liyang Chip first announced the plan at the end of December 2024. The company signed a letter of intent with six individuals who collectively owned Guoxin Micro, a Chongqing-based chip-testing provider.

The proposed transaction covered all of the target’s equity. However, the original acquisition notice made clear that the document represented preliminary intent rather than a final transfer agreement.

The parties had not settled the purchase price. That figure was supposed to follow due diligence, auditing, valuation work, and further negotiation.

Liyang Chip also said at the time that the proposal was not expected to qualify as a major asset restructuring under applicable Chinese rules. The letter of intent therefore established a possible route toward an acquisition without guaranteeing that the transaction would proceed.

Over the following 20 months, Liyang Chip and its advisers examined Guoxin Micro from legal, financial, business, and technical perspectives. Management also conducted several rounds of internal analysis.

The review did not produce final transaction terms. On September 4, Liyang Chip said the conditions for completing the deal were not mature, according to the company’s termination disclosure.

That phrase leaves the decisive obstacle unidentified. The company did not publicly attribute the failure to valuation, regulatory approval, financing, intellectual property, customer concentration, or a technical problem.

The two sides instead ended the process by mutual agreement. Their termination contract canceled the letter of intent except for continuing confidentiality obligations.

They reported no dispute, default, or unresolved claim. Neither side bears a termination penalty, and the company said the decision would not affect its financial position or operating results.

Those details matter because they define what investors can reasonably infer. The announcement does not describe a failed integration, an impairment charge, or money that must be recovered.

It describes a proposed purchase that never became binding. Consequently, the immediate accounting consequences appear limited, while the lost strategic opportunity remains more significant.

This distinction also explains why the headline number needs context. The 100 referred to the percentage of Guoxin Micro’s equity under consideration, not a disclosed valuation, payment, or operating target.

The event is therefore less about the cost of withdrawing and more about the capability Liyang Chip expected to obtain. Understanding that capability reveals why a financially clean exit still creates pressure.

Why the 100% Guoxin Micro Deal Mattered

Guoxin Micro offered more than additional testing volume because it held laboratory capabilities and qualifications that Liyang Chip identified as a missing part of its portfolio.

Guoxin Micro was founded in 2019 as an independent provider of integrated-circuit testing solutions. Its services included wafer testing, finished-chip testing, and module testing.

Wafer testing examines chips before a silicon wafer is cut into individual units. Finished-chip testing checks packaged devices before shipment, while module testing evaluates chips inside a larger functional assembly.

The company also operated an independent laboratory and analysis platform. Its stated capabilities covered identification, inspection, screening, reliability testing, and failure analysis for specialized components, chips, and modules.

Failure analysis is the process of finding why a semiconductor device stopped meeting its required electrical or physical performance. It can determine whether a problem came from design, fabrication, packaging, materials, or operating conditions.

Guoxin Micro had obtained CNAS laboratory recognition and CMA inspection credentials, according to disclosures cited when the transaction was announced. It also held qualifications associated with specialized industry work.

These credentials were central to Liyang Chip’s rationale. The buyer said Guoxin Micro could fill its gap in specialized-chip testing while combining the companies’ technical, market, and qualification resources.

A qualification cannot always be reproduced by purchasing another tester. Laboratories must establish controlled procedures, trained personnel, documented quality systems, traceable measurements, and acceptable facilities.

Customers in sensitive applications also evaluate a supplier’s operating record. Building the required trust can take longer than installing the physical equipment.

That made acquisition an appealing shortcut. Liyang Chip could potentially have added Guoxin Micro’s laboratory platform, experienced staff, and recognized scope alongside its existing wafer and finished-chip testing operations.

The target was also smaller than Liyang Chip. Securities Times reported that Guoxin Micro had invested about RMB 80 million in its testing factory and generated approximately RMB 80 million in 2023 sales.

Those figures came from public reporting rather than the termination announcement. They help explain why the proposed deal promised a focused capability expansion instead of a merger between similarly sized businesses.

The initial filing said Guoxin Micro had registered capital of RMB 15.8 million. It also identified three invention patents and 22 software copyrights, with additional intellectual property applications pending at the time.

Liyang Chip’s strategy was therefore easy to understand. It would buy a complete specialist rather than develop every laboratory process, qualification, customer relationship, and software asset independently.

The cancellation reverses that plan. It does not mean Liyang Chip cannot serve automotive, industrial, memory, or computing customers through its current facilities.

It means the company has not obtained the specific platform it presented as a way to close its specialized-testing gap. That difference will shape how the market evaluates its next investments.

The company can build internally, seek partnerships, or pursue another target. Each route requires time, capital, management attention, or dependence on an outside party.

A Clean Exit Meets a Recovering Core Business

Liyang Chip abandoned the deal just as its existing testing operation produced its strongest evidence of recovery.

The company reported first-half 2026 revenue of RMB 356.33 million, up 25.45% from RMB 284.04 million one year earlier. It described that revenue as a record for any first half since the company’s establishment.

Net income attributable to shareholders reached RMB 15.37 million. That compared with a RMB 7.06 million loss during the first half of 2025.

Operating cash flow rose to RMB 148.14 million from RMB 100.79 million, an increase of 46.98%. These figures come from Liyang Chip’s official half-year report, which was not audited.

The turnaround changes the context around the canceled acquisition. Liyang Chip is not retreating while reporting an accelerating operating decline.

Its existing business gained demand from memory, automotive electronics, industrial control, AIoT, and system-on-chip products. The company said several important customers completed qualification work and moved chips into volume production.

Integrated-circuit testing revenue reached about RMB 346 million during the half, according to Securities Times. That represented roughly 97% of total company revenue and increased about 25% from the prior year.

The concentration shows why management remains focused on testing. It also reveals the limits of the current recovery because most revenue still comes from the same core activity.

Liyang Chip spent RMB 39.57 million on research and development during the period. That equaled 11.11% of revenue, even though the ratio declined as sales grew faster than research spending.

The company’s 2025 annual report had identified high-performance processors, automotive electronics, communications, sensors, memory, AI, autonomous driving, and embodied intelligence as intended testing markets. Management also planned to increase investment in equipment and technical development.

Those plans offer an organic alternative to acquisition. Stronger revenue and operating cash generation give Liyang Chip more room to add capacity or develop testing programs internally.

However, higher demand does not automatically create specialized laboratory qualifications. Volume growth in mainstream testing and access to sensitive verification work remain related but distinct objectives.

The cancellation can still help management concentrate resources. A proposed acquisition requires technical diligence, legal review, valuation analysis, negotiations, and preparations for possible integration.

Ending the process removes those demands. It also prevents Liyang Chip from accepting a transaction whose final economics or conditions failed to satisfy management after prolonged review.

That discipline matters in semiconductor acquisitions. Assets can become expensive when buyers compete for proven technology, scarce technical staff, qualifications, and established customer relationships.

The market should therefore avoid treating deal completion as inherently superior to cancellation. A strategically attractive asset can still become an unattractive purchase under the wrong terms.

The opposite conclusion would also go too far. Liyang Chip’s improved results do not prove that organic development can replace everything the target offered.

The central contest is now clear: financial and operational discipline versus faster access to specialized testing capabilities. The recovery strengthens Liyang Chip’s ability to choose, but it does not eliminate that choice.

The Missing Explanation Is the Biggest Risk

Investors received a clear description of the termination process but little evidence about the condition that prevented a final agreement.

Liyang Chip said the transaction conditions were not mature after extensive review. That wording confirms that the parties found no acceptable route to closing, but it does not identify the disputed issue.

Several possibilities commonly derail acquisitions. Buyers and sellers can disagree on valuation, payment structure, performance commitments, liability allocation, or control after closing.

Due diligence can also uncover customer concentration, qualification limitations, uncertain earnings quality, intellectual-property concerns, or capital requirements. None of those explanations has been confirmed in this case.

Readers should not interpret silence as proof of a specific defect. The termination agreement states that the parties had no dispute or breach, while the company said it never paid consideration.

Still, the information gap constrains any confident assessment. Without a price, audited target accounts, detailed valuation assumptions, or a named obstacle, outsiders cannot measure what Liyang Chip rejected.

This is particularly important because the proposal remained alive for more than a year and a half. In July 2025, the company told investors that due diligence and assessment were continuing and that its acquisition plan had not changed.

The process then continued into September 2026. A review of that length suggests that management did more than reconsider an early idea, although the disclosure does not reveal when the decisive problem emerged.

The episode also fits a broader pattern in China’s semiconductor market. Companies have pursued acquisitions to obtain technology, production assets, product lines, and qualified technical teams faster than internal development permits.

Many proposed combinations have nevertheless struggled to bridge valuation and ownership differences. Caixin reported that about 9% of announced Chinese semiconductor acquisitions had been terminated during 2025.

Separate deal failure data from CVSource counted 496 semiconductor merger and acquisition cases during 2025, including 32 failed transactions. Their disclosed aggregate value reached RMB 279.67 billion.

These industry figures do not explain the Guoxin Micro decision. They show why “conditions were not mature” cannot automatically be read as an unusual technical failure.

A public semiconductor buyer faces competing pressures during negotiations. It wants scarce capabilities, but it must also justify the price, financing, governance, and expected return to shareholders.

Private target owners may value future growth, qualifications, or technical scarcity more aggressively. The buyer must evaluate current earnings and the additional investment required after closing.

Semiconductor testing creates further complexity. Equipment value, utilization, customer qualification, engineering talent, and the durability of service contracts can each affect a target’s economic worth.

Laboratory credentials also have defined scopes. A credential’s value depends on which tests, devices, facilities, and procedures it actually covers, not simply whether the certificate exists.

Liyang Chip has not said that any Guoxin Micro qualification was deficient. The point is that these details would matter to a buyer and remain unavailable to public readers.

The cautious conclusion is narrow. The company avoided immediate financial exposure, but investors cannot determine whether it walked away because the target was unsuitable, the terms were unattractive, or agreement simply took too long.

The Competitive Gap Will Not Wait for Another Deal

Liyang Chip’s competitors and customers will continue investing while the company chooses a replacement route for specialized testing.

Independent testing providers occupy a specific position in the semiconductor supply chain. They perform testing without necessarily manufacturing wafers or packaging the resulting chips.

That independence can appeal to fabless designers, which create chip designs while outsourcing physical production. It can also provide customers with flexible capacity and engineering support across different manufacturing partners.

Liyang Chip competes for work against other independent testing specialists and larger outsourced semiconductor assembly and test companies. The latter combine packaging and testing within broader production networks.

Large providers can spread equipment, engineering, and qualification costs across more customers. Specialist firms can answer with focused programs, closer engineering collaboration, or expertise in less standardized devices.

The competitive contest therefore involves more than installed capacity. Providers must develop test programs, shorten product-introduction cycles, improve utilization, and support increasingly complex devices.

AI processors, high-bandwidth memory, automotive chips, and industrial controllers raise different testing demands. Higher power, faster interfaces, greater device complexity, and stricter reliability requirements can increase both test time and technical difficulty.

A 2026 testing-market study from Frost & Sullivan estimated that the global semiconductor comprehensive-testing solutions market grew from RMB 70.4 billion in 2021 to RMB 133.6 billion in 2025. That implies a 17.4% compound annual growth rate.

The study covers a wider market than Liyang Chip’s exact service category, so it should not be treated as the company’s addressable revenue. It does illustrate why testing capabilities have attracted investment and acquisition interest.

Liyang Chip’s first-half growth shows that it already participates in several favorable demand areas. The company cited memory, automotive electronics, industrial control, edge intelligence, and system-on-chip products as revenue drivers.

Yet customers do not award every program solely because a supplier serves an adjacent market. New chips often require device-specific software, hardware interfaces, engineering validation, and production qualification.

Specialized applications can add laboratory accreditation, reliability protocols, screening procedures, and security requirements. These are the capabilities that gave the Guoxin Micro proposal strategic relevance.

Management now faces three realistic routes. It can invest internally, cooperate with qualified laboratories, or look for another acquisition.

Internal development gives Liyang Chip more control and avoids integration risk. It can also require the longest path because equipment, personnel, procedures, audits, and customer acceptance must develop together.

Partnerships can provide faster access without buying an entire company. However, Liyang Chip would share economics and depend on another organization for capacity, scheduling, and quality execution.

Another acquisition could recreate the original logic. It would also repeat the challenges of valuation, due diligence, negotiation, and integration that accompanied the Guoxin Micro process.

No route is automatically best. The correct choice depends on customer commitments, capability gaps, expected utilization, capital needs, and how quickly demand becomes available.

The competitive risk comes from delay without a clear substitute. A clean termination preserves capital, but preserved capital only creates value when management deploys it effectively.

Three Signals Will Show What Comes Next

The next test is whether Liyang Chip converts its clean exit into a specific operating plan before the missing capability becomes a lasting constraint.

The first signal is a disclosed replacement strategy. Investors should watch for a new acquisition proposal, a laboratory partnership, or an organic specialized-testing project.

A named project with defined capabilities would strengthen the view that Liyang Chip canceled one transaction without abandoning its strategic objective. Continued silence would suggest that the capability gap has moved lower on management’s priority list.

The second signal is the composition of testing revenue. Total growth matters, but revenue from automotive, computing, industrial, memory, and other demanding applications will show whether the company is moving toward higher-value programs.

Customer qualification announcements also deserve attention. A successful production qualification proves more than a general statement about market demand because it connects technical capability with a commercial program.

The third signal is financial execution during the second half of 2026. Revenue growth, equipment utilization, research spending, operating cash flow, and sustainable profitability will reveal whether the first-half recovery has staying power.

Strong results would support management’s ability to fund internal development or negotiate future deals from a better position. Weaker cash generation would increase the tradeoff between expansion and balance-sheet discipline.

Investors should also maintain a clear burden of proof. The company’s statement that the termination will not affect current performance addresses immediate financial consequences, not future opportunity costs.

The Guoxin Micro deal explained one possible path into specialized laboratory verification. Its cancellation removes that path until management identifies another.

This is why the decision is more consequential than an ordinary abandoned letter of intent. Liyang Chip spent roughly 20 months examining an asset intended to fill a stated strategic gap, then exited without disclosing the decisive barrier.

At the same time, the company avoided payment, penalties, and a potentially unsuitable commitment. Its core operation entered the second half with higher revenue, positive earnings, and stronger operating cash flow.

The next one to three months should clarify which side of that balance matters more. Watch for a replacement capability plan, evidence of higher-value customer qualifications, and financial results that support continued investment.

The 100% acquisition is over, but the original business problem remains. Liyang Chip must now show whether discipline delayed its expansion or protected the company while it builds a better route forward.